Ascend Advanced Therapies Successfully Defends European Patent for EpyQ AAV Plasmid Technology
Key Insights
Ascend Advanced Therapies (search) successfully defended its European patent EP3722434 protecting EpyQ (search) AAV (search) plasmid technology in opposition proceedings before the European Patent Office.
The EPO decision confirms the novelty and robustness of Ascend's proprietary approach to AAV (search) plasmid design and production for gene therapy applications.
The patent defense strengthens Ascend's intellectual property position and reinforces its leadership in AAV (search) plasmid technology for genetic medicine development.
Ascend Advanced Therapies (search) announced that its European patent EP3722434, protecting the company's proprietary EpyQ (search) AAV (search) plasmid technology, has been successfully defended in opposition proceedings before the European Patent Office (EPO). The decision confirms the novelty and robustness of Ascend's pioneering approach to AAV plasmid design and production.
Patent Defense Validates Technology Innovation
Opposition proceedings at the EPO represent a rigorous challenge to patentability, making the decision to uphold the patent a significant validation of the intellectual property behind EpyQ (search) technology. The successful defense underscores the strength and uniqueness of Ascend's AAV (search) plasmid platform in the competitive gene therapy landscape.
"This is a landmark achievement for our company," said Markus Hörer, Ascend's Chief Scientific Officer. "By defending our EpyQ (search) patent, we have not only secured our innovation but also reinforced our position as a leader in AAV (search) plasmid technology. This decision strengthens our ability to support partners in advancing gene therapy development with confidence in the IP landscape."
Strengthening Gene Therapy Development Platform
The successful maintenance of this patent provides a strong foundation for the continued development and application of EpyQ (search) technology in the rapidly evolving field of gene therapy. Ascend's team remains committed to delivering cutting-edge AAV (search) plasmid and vector solutions that enable innovation and accelerate progress in genetic medicine.
Company Background
Ascend Advanced Therapies (search) operates as a gene-to-GMP contract development and manufacturing organization (CDMO) specializing in high-quality, cost-effective advanced therapy development and manufacturing. The company launched in early 2023 with the acquisition of Freeline Therapeutics Munich manufacturing assets and development team with AAV (search) development expertise dating from 1991.
In early 2024, Ascend acquired GMP manufacturing assets from Beacon Therapeutics in Alachua, Florida to establish a United States footprint. In late 2024, Ascend aligned with ABL, Inc. to expand development, manufacturing and fill/finish capabilities for gene therapies, oncolytics, vaccines and immunotherapies.
The company's foundational investors include Abingworth, Ajinomoto, Cathay Health, Deerfield, Digitalis Ventures, DCVC Bio, EW Healthcare Partners, 4BIO Capital, Monograph, and Petrichor.